{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:32:56Z","timestamp":1760142776045,"version":"build-2065373602"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"DOI":"10.7759\/cureus.94278","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:22:18Z","timestamp":1760102538000},"source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response"],"prefix":"10.7759","author":[{"given":"Zemmez","family":"Youssef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed-amine","family":"Ennaciri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Frikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoufal","family":"Hjira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231168839","article-title":"Alopecia areata: an updated review for 2023","volume":"27","author":"Sibbald C","year":"2023","unstructured":"Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023, 27:241-59. 10.1177\/12034754231168839","journal-title":"J Cutan Med Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu LY","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018, 79:556-8.e1. 10.1016\/j.jaad.2018.01.048","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.086","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","volume":"88","author":"Okhovat JP","year":"2023","unstructured":"Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023, 88:1040-50. 10.1016\/j.jaad.2019.05.086","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563286","article-title":"JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid","volume":"16","author":"Lin X","year":"2025","unstructured":"Lin X, Li X, Zhai Z, Zhang M. JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2025, 16:1563286. 10.3389\/fimmu.2025.1563286","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot HA","year":"2023","unstructured":"Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023, 98:656-77. 10.1016\/j.abd.2023.03.001","journal-title":"An Bras Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5546\/aap.2017.eng.e404","article-title":"Alopecia areata. Current situation and perspectives","volume":"115","author":"Ju\u00e1rez-Rend\u00f3n KJ","year":"2017","unstructured":"Ju\u00e1rez-Rend\u00f3n KJ, Rivera S\u00e1nchez G, Reyes-L\u00f3pez M\u00c1, Garc\u00eda-Ortiz JE, Bocanegra-Garc\u00eda V, Guardiola-Avila I, Altamirano-Garc\u00eda ML. Alopecia areata. Current situation and perspectives. Arch Argent Pediatr. 2017, 115:e404-11. 10.5546\/aap.2017.eng.e404","journal-title":"Arch Argent Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621492","article-title":"From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology","volume":"16","author":"Zhao HB","year":"2025","unstructured":"Zhao HB, Zhang YN, Qiang Y, Wang GM, Wang LW, Jiang WC, Chen X. From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology. Front Immunol. 2025, 16:1621492. 10.3389\/fimmu.2025.1621492","journal-title":"Front Immunol"},{"key":"ref8","unstructured":"FDA approves first systemic treatment for alopecia areata. (2022). Accessed. September 17, 2025: https:\/\/www.prnewswire.com\/news-releases\/fda-approves-first-systemic-treatment-for-alopecia-areata-301566884.html."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01030-x","article-title":"Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data","volume":"13","author":"De Greef A","year":"2023","unstructured":"De Greef A, Thirion R, Ghislain PD, Baeck M. Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data. Dermatol Ther (Heidelb). 2023, 13:2869-77. 10.1007\/s13555-023-01030-x","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King B","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al.. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022, 386:1687-99. 10.1056\/NEJMoa2110343","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2444494","article-title":"Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study","volume":"36","author":"Vignoli CA","year":"2025","unstructured":"Vignoli CA, Gargiulo L, Ibba L, et al.. Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study. J Dermatolog Treat. 2025, 36:2444494. 10.1080\/09546634.2024.2444494","journal-title":"J Dermatolog Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17829","article-title":"Long-term real-world outcomes of baricitinib in severe alopecia areata: a 104-week retrospective analysis from a single Institute","volume":"52","author":"Wada-Irimada M","year":"2025","unstructured":"Wada-Irimada M, Takahashi T, Sekine M, et al.. Long-term real-world outcomes of baricitinib in severe alopecia areata: a 104-week retrospective analysis from a single Institute. J Dermatol. 2025, 52:1321-5. 10.1111\/1346-8138.17829","journal-title":"J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20691","article-title":"Strong efficacy of ritlecitinib 50\u2009mg and baricitinib 4\u2009mg in alopecia areata, but further research needed to establish superiority","volume":"39","author":"Saceda-Corralo D","year":"2025","unstructured":"Saceda-Corralo D, Va\u00f1\u00f3-Galv\u00e1n S. Strong efficacy of ritlecitinib 50\u2009mg and baricitinib 4\u2009mg in alopecia areata, but further research needed to establish superiority. J Eur Acad Dermatol Venereol. 2025, 39:1072-3. 10.1111\/jdv.20691","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.53933\/943cpk09","article-title":"Modern and promising strategies for treatment of alopecia in the United States: clinical and pharmacological, marketing, regulatory, SWOT analysis","volume":"5","author":"Malaniuk K","year":"2025","unstructured":"Malaniuk K. Modern and promising strategies for treatment of alopecia in the United States: clinical and pharmacological, marketing, regulatory, SWOT analysis. SSP Mod Pharm Med. 2025, 5:107-20. 10.53933\/943cpk09","journal-title":"SSP Mod Pharm Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420508-baricitinib-in-the-management-of-severe-alopecia-areata-a-report-of-two-cases-with-sustained-clinical-response","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:22:19Z","timestamp":1760102539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420508-baricitinib-in-the-management-of-severe-alopecia-areata-a-report-of-two-cases-with-sustained-clinical-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.94278","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}